Clinical Trial Detail

NCT ID NCT03298516
Title A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.
Indications

acute myeloid leukemia

Therapies

DCLL9718S

Azacitidine + DCLL9718S

Age Groups: adult senior

No variant requirements are available.